FDA Approves Second Remicade Biosimilar: Samsung Bioepis’ Renflexis

The FDA approved Renflexis, a biosimilar of Remicade, in several indications including rheumatoid arthritis, plaque psoriasis and Crohn’s disease.
Source: Drug Industry Daily